Estadísticas de Survival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumab

Visitas totales

views
Survival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumab 0

Visitas totales por mes

views
noviembre 2023 0
diciembre 2023 0
enero 2024 0
febrero 2024 0
marzo 2024 0
abril 2024 0
mayo 2024 0